New drug duo targets Hard-to-Treat lung cancer
NCT ID NCT07264816
First seen Jan 08, 2026 · Last updated Jun 20, 2026 · Updated 27 times
Summary
This study tests a combination of two drugs, BL-M07D1 and pembrolizumab, in people with advanced non-squamous non-small cell lung cancer that has high levels of a protein called HER2. The goal is to see if the combination shrinks tumors and how safe it is. About 80 adults aged 18 to 75 are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M07D1 (a drug given by IV) and pembrolizumab (an immunotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with a specific type of advanced lung cancer that has HER2 overexpression.
What could go wrong
This is an early Phase II trial with only 80 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.